Document is current
Any future updates will be listed below
-
Authors
Ciliberto, Gennaro
Canfora, Marco
Terrenato, Irene
Agnoletto, Chiara
Agustoni, Francesco
Amoroso, Loredana
Baldassarre, Gustavo
Curigliano, Giuseppe
Delmonte, Angelo
De Luca, Antonella
Fiorentino, Michelangelo
Gregorc, Vanesa
Ibrahim, Toni
Lazzari, Chiara
Mastronuzzi, Angela
Pronzato, Paolo
Santoro, Armando
Scambia, Giovanni
Tommasi, Stefania
Vingiani, Andrea
Giacomini, Patrizio https://orcid.org/0000-0001-6109-1709
De Maria, Ruggero
-
Funding
Funding for this research was provided by:
Alliance Against Cancer Resources
- License Information
-
More Information
Article History
Received: 25 July 2022
Accepted: 4 October 2022
First Online: 17 October 2022
Declarations
:
: Not applicable.
: Not applicable.
: GCu declares advisory board for BMS, Roche, Merck, Daichii Sankyo, Astra Zeneca, Lilly, Pfizer, Novartis, Celcuity, Exact Sciences, Gilead, Seagen. AS: advisory board for BMS, Servier, Gilead, Pfizer, Eisai, Bayer, MSD. Consultancy: Arqule, Sanofi, Incyte. Speaker's Bureau: Takeda, BMS, Roche, Abb-Vie, Amgen, Celgene, Servier, Gilead, Astrazeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD.
